ArticleJournal of materials science. Materials in medicine2026
Lansoprazole incorporated β-chitin-lyophilised PRF composite hydrogel for treatment of gastric ulcer.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A gastric ulcer (GU) that leads to acute or persistent bleeding poses a considerable risk of fatalities. Despite their overall primacy, the current treatments for GU have major downsides of incomplete healing, antibiotic resistance, and secondary injury. To address these challenges, researchers have turned their attention to hydrogels to solve the therapeutic bottleneck of GU treatment. Based on this, we developed a β-chitin (β-ch) hydrogel incorporating Lyophilised Platelet-rich fibrin (L-PRF) with anti-ulcer drug Lansoprazole (Lns). The prepared hydrogel was characterized using FESEM and FT-IR. In vitro studies of all samples showed good controlled swelling behaviour and degradation rate. Incorporation of Lansoprazole (Lns) facilitates healing and promotes and gastric mucosal regeneration, potentially through its acid-suppressive effects, whereas the in vitro drug release study proved the sustained release of Lns from the prepared hydrogel. The in vitro growth factor release study using ELISA revealed a sustained release of TGFα and PDGF BB. The Lansoprazole incorporated hydrogels exhibited good antioxidant activity. Further, β-ch-L-PRF-Lns hydrogel was demonstrated to be biocompatible in nature, and enhanced cell attachment of β-ch -L-PRF-Lns hydrogel was also observed in intestinal cells (INT 407). The INT 407 cells exposed to Lns incorporated β-ch-L-PRF hydrogel showed enhanced cell migration. Therefore, this unique strategy accelerates regenerative processes, making it a possible effective therapeutic alternative for treating GU.
Indexed as
Identifiers
42479084What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.